XML 58 R34.htm IDEA: XBRL DOCUMENT v3.24.4
Fair Value of Financial Instruments (Tables)
6 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at December 31, 2024:
TotalQuoted
prices in
active
markets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
 (in thousands)
Assets:
Deferred compensation plan investments, current and non-current$31,852 $31,852 $ $ 
Interest rate swap agreement1,658  1,658  
Foreign currency hedge30  30  
Total assets at fair value$33,540 $31,852 $1,688 $ 
Liabilities:
Deferred compensation plan investments, current and non-current$31,793 $31,793 $ $ 
Forward foreign currency exchange contracts24  24  
Liability for contingent consideration, current and non-current18,343   18,343 
Total liabilities at fair value$50,160 $31,793 $24 $18,343 

The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at June 30, 2024:
TotalQuoted
prices in
active
markets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
 (in thousands)
Assets:
Deferred compensation plan investments, current and non-current $31,014 $31,014 $— $— 
Foreign currency hedge345 — 345 — 
Interest rate swap agreement2,698 — 2,698 — 
Total assets at fair value$34,057 $31,014 $3,043 $— 
Liabilities:
Deferred compensation plan investments, current and non-current$31,014 $31,014 $— $— 
Forward foreign currency exchange contracts12 — 12 — 
Total liabilities at fair value$31,026 $31,014 $12 $— 
Schedule of Changes in Fair Value of Contingent Considerations
The following tables represent the Company's contingent consideration liabilities at fair value at December 31, 2024:
Quarter ended December 31, 2024
 Specialty Technology SolutionsIntelisys & AdvisoryTotal
 (in thousands)
Fair value at beginning of period$7,500 $9,700 $17,200 
Change in fair value of contingent consideration473 670 1,143 
Fair value at end of period$7,973 $10,370 $18,343 
Six months ended December 31, 2024
Specialty Technology SolutionsIntelisys & AdvisoryTotal
(in thousands)
Fair value at beginning of period$ $ $ 
Issuance of contingent consideration7,500 9,700 17,200 
Change in fair value of contingent consideration473 670 1,143 
Fair value at end of period$7,973 $10,370 $18,343 
Valuation techniques and significant observable inputs used in recurring Level 3 fair value measurements for the Company's contingent consideration liabilities related to Advantix and Resourcive at December 31, 2024 were as follows.
AcquisitionReporting PeriodValuation TechniqueSignificant Unobservable InputsWeighted Average Rates
AdvantixDecember 31, 2024Discounted cash flowAdjusted EBITDA risk premium15.7 %
Adjusted EBITDA growth rate19.8 %
ResourciveDecember 31, 2024Monte CarloAdjusted EBITDA risk premium13.7 %
Simulated commission growth percentage23.0 %